RA Capital has led a $100m series B round for Ventus Therapeutics, which is linked to multiple universities.
RA Capital Management has led a series B round for the UW-linked vaccine developer, which had raised $51m in a series A 18 months ago.
The cancer treatment developer, co-founded by researchers from University of Chicago, has secured funding in a round co-led by Arix Bioscience and RTW Investments.
The developer of epigenetic medicine, based on Whitehead Institute research, pulled in funding through a round led by founding investor Flagship Pioneering.
Ohio State University spinout Entrada Therapeutics has pocketed $116m in a series B round.
Cambridge Innovation Capital has returned for a series C round for University of Cambridge-linked Gyroscope Therapeutics, which also welcomed back Syncona.
Evidation, co-founded by Stanford University and GE Ventures, has picked up series E funding at a $1bn valuation.
ActionIQ has pushed its series C round to $100m following an extension from existing shareholders.